Taxane Pro-Emulsion Formulations for Enhanced Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The poor solubility of taxane molecules in both aqueous and lipid carriers makes it difficult to formulate them into therapeutically effective carriers for cancer treatment, limiting their administration and efficacy.
Innovation Solution
Taxane pro-emulsion formulations are developed, comprising a dried powder of taxane, oil, surfactant, and sugar alcohol, which, when combined with an aqueous medium, produce a clear emulsion with a particle size similar to the precursor emulsion, enhancing solubility and stability for effective administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If taxane is formulated in traditional aqueous or lipid carriers, then the formulation is simple, but the solubility of taxane is poor
Solution Approach 1:
The patent employs a composite emulsion formulation consisting of multiple components: taxane (active ingredient), oil phase (for solubility), surfactant (for emulsification), and sugar alcohol (for stability and solubility enhancement). This composite approach allows the hydrophobic taxane to be effectively delivered in an aqueous environment by combining materials with complementary properties, resolving the contradiction between solubility and formulation simplicity.
2Reliability
If taxane pro-emulsion formulations are developed with multiple components, then the solubility and stability are improved, but the formulation complexity increases
Solution Approach 1:
The patent optimizes specific parameter ranges for each component: oil phase (0.1-10% w/v), surfactant (10-70% w/v), sugar alcohol (15-80% w/v), and non-aqueous solvent (0.1-30% w/v). By defining precise parameter ranges, the formulation achieves reliable stability and solubility while controlling complexity through standardized preparation protocols. The emulsion particle size is controlled at 70 nm or less, which also contributes to stability.
3Stability of the object's composition
If the particle size is reduced to 70 nm or less, then the emulsion clarity and stability are improved, but the manufacturing precision requirements increase
Solution Approach 1:
The patent employs preliminary emulsification steps where the oil phase, surfactant, and taxane are mixed and emulsified before adding the aqueous phase. This pre-emulsification creates a stable initial dispersion that is easier to control during subsequent homogenization. The use of sugar alcohol as a co-solvent and stabilizer also facilitates particle size control at 70 nm or less by preventing aggregation during the manufacturing process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The taxane pro-emulsion formulations achieve stable and effective emulsification, maintaining the activity of taxane active agents, allowing for improved administration and treatment of cellular proliferative diseases such as cancer, with clear emulsions having particle sizes of 70 nm or less, ensuring effective drug delivery and stability.
Implementation Method 1
a surfactant; and a sugar alcohol wherein the powder is formulated to produce upon combination with an aqueous medium a clear emulsion
Implementation Method 2
produce upon combination with an aqueous medium a clear emulsion
Data Source
AI summary
Taxane pro-emulsion formulations are provided. Pro-emulsion formulations are dried powders that include a taxane, oil, surfactant and sugar alcohol. Also provided are methods of making and using the pro-emulsion formulations, as well as kits that include the pro-emulsion formulations.